1. Home
  2. DRH vs IMCR Comparison

DRH vs IMCR Comparison

Compare DRH & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diamondrock Hospitality Company

DRH

Diamondrock Hospitality Company

HOLD

Current Price

$9.21

Market Cap

1.9B

Sector

Real Estate

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$29.59

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRH
IMCR
Founded
2004
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
DRH
IMCR
Price
$9.21
$29.59
Analyst Decision
Buy
Buy
Analyst Count
8
12
Target Price
$9.84
$61.82
AVG Volume (30 Days)
2.0M
349.0K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
3.79%
N/A
EPS Growth
N/A
30.39
EPS
N/A
N/A
Revenue
N/A
$249,428,000.00
Revenue This Year
$2.99
$14.39
Revenue Next Year
$1.99
$8.19
P/E Ratio
$38.41
N/A
Revenue Growth
N/A
43.05
52 Week Low
$6.19
$23.15
52 Week High
$10.67
$40.71

Technical Indicators

Market Signals
Indicator
DRH
IMCR
Relative Strength Index (RSI) 38.34 34.86
Support Level $9.05 N/A
Resistance Level $9.37 $34.35
Average True Range (ATR) 0.26 1.37
MACD -0.06 -0.26
Stochastic Oscillator 0.58 3.46

Price Performance

Historical Comparison
DRH
IMCR

About DRH Diamondrock Hospitality Company

Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The revenue is divided between room, food and beverage, and others. The room segment contributes the majority of the revenue. The firm's customers include leisure transients, business transients, and group customers.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: